CHA News Article

FDA Fixes Issues With Online Certification for Schizophrenia Medication

The Food and Drug Administration (FDA) has notified providers that it has resolved technical problems with the Clozapine Risk Evaluation and Mitigation Strategy Program, and that prescribers and pharmacies should now be able to complete their online certification for the program. Clozapine is a medication for schizophrenia, and last month the FDA issued new monitoring, prescribing, dispensing and receiving requirements, attempting to address concerns about a serious blood condition called neutropenia that is sometimes associated with the medication. If prescribers or pharmacists encounter additional problems with the program, they should contact the FDA at (844) 267-8678.